Biogen

Biogen logo
🇺🇸United States
Ownership
Private
Established
1978-01-01
Employees
7.5K
Market Cap
$29.6B
Website
https://www.biogen.com
Introduction

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMAD...

A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors

Phase 1
Completed
Conditions
First Posted Date
2008-05-08
Last Posted Date
2013-09-16
Lead Sponsor
Biogen
Target Recruit Count
55
Registration Number
NCT00674947
Locations
🇺🇸

Research Site, San Antonio, Texas, United States

104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2008-04-23
Last Posted Date
2016-01-21
Lead Sponsor
Biogen
Target Recruit Count
339
Registration Number
NCT00664573
Locations
🇬🇧

Coordinating Research Site, Leeds, Yorkshire, United Kingdom

Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants

First Posted Date
2008-04-23
Last Posted Date
2016-01-21
Lead Sponsor
Biogen
Target Recruit Count
391
Registration Number
NCT00664716
Locations
🇬🇧

Coordinating Research Site, Leeds, Yorkshire, United Kingdom

Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2008-04-02
Last Posted Date
2011-01-07
Lead Sponsor
Biogen
Target Recruit Count
20
Registration Number
NCT00651443
Locations
🇺🇸

Research Site, Buffalo, New York, United States

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-02-20
Last Posted Date
2015-10-02
Lead Sponsor
Biogen
Target Recruit Count
20
Registration Number
NCT00618319
Locations
🇺🇸

Research Site, Santa Monica, California, United States

🇺🇸

Reseach Facility, San Antonio, Texas, United States

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-02-20
Last Posted Date
2016-12-29
Lead Sponsor
Biogen
Target Recruit Count
68
Registration Number
NCT00618735
Locations
🇺🇸

Research Site, San Antonio, Texas, United States

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

Completed
Conditions
First Posted Date
2008-02-20
Last Posted Date
2010-03-05
Lead Sponsor
Biogen
Target Recruit Count
100
Registration Number
NCT00618267
Locations
🇺🇸

Brigham and Women's Hospital - Partners MS Center, Brookline, Massachusetts, United States

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

First Posted Date
2008-02-15
Last Posted Date
2014-08-13
Lead Sponsor
Biogen
Target Recruit Count
123
Registration Number
NCT00616434
Locations
🇸🇰

Investigator, Trencin, Slovakia

🇷🇺

Investiator, Yaroslavl, Russian Federation

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis

Completed
Conditions
Interventions
First Posted Date
2008-01-23
Last Posted Date
2010-01-27
Lead Sponsor
Biogen
Target Recruit Count
136
Registration Number
NCT00599274
Locations
🇺🇸

Research Site, Milwaukee, Wisconsin, United States

🇨🇦

Coordinating Research Site, Halifax, Nova Scotia, Canada

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Phase 1
Completed
Conditions
Interventions
First Posted Date
2007-12-17
Last Posted Date
2012-06-08
Lead Sponsor
Biogen
Target Recruit Count
42
Registration Number
NCT00575068
Locations
🇺🇸

Research Site, Durham, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath